
China Approves First Solid Tumor CAR-T Therapy
China’s National Medical Products Administration has authorized Satri-cel, the world’s inaugural CAR-T cell treatment for solid tumors. This milestone targets Claudin18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma, offering a new clinical pathway for patients who have exhausted at least two previous lines of standard therapeutic intervention.





















